Sirtuin-3 (Sirt3) is an essential metabolic regulatory enzyme that plays an important role in mitochondrial metabolism, but its role in bone marrow and skeletal homeostasis remains largely unknown. In this study, we hypothesize that increased expression of Sirt3 plays a role in skeletal aging. Using mice that overexpress Sirt3 [i.e., Sirt3 transgenic (Sirt3Tg)], we show that Sirt3 is a positive regulator of adipogenesis and osteoclastogenesis and a negative regulator of skeletal homeostasis. Sirt3Tg mice exhibited more adipocytes in the tibia compared with control mice. Bone marrow stromal cells (BMSCs) from Sirt3Tg mice displayed an enhanced ability to differentiate into adipocytes compared with control BMSCs. We found a 2.5-fold increase in the number of osteoclasts on the bone surface in Sirt3Tg mice compared with control mice (P , 0.03), and increased osteoclastogenesis in vitro. Importantly, Sirt3 activates the mechanistic target of rapamycin (mTOR) pathway to regulate osteoclastogenesis. Sirt3Tg male mice exhibited a significant reduction in cortical thickness at the tibiofibular junction (P , 0.05). In summary, Sirt3 activity in bone marrow cells is associated with increased adipogenesis, increased osteoclastogenesis through activation of mTOR signaling, and reduced bone mass. Interestingly, Sirt3 expression in bone marrow cells increases during aging, suggesting that Sirt3 promotes age-related adipogenesis and osteoclastogenesis associated with bone loss. These findings identify Sirt3 as an important regulator of adipogenesis and skeletal homeostasis in vivo and identify Sirt3 as a potential target for the treatment of osteoporosis. (Endocrinology 158: 2741-2753, 2017) B one resorption and formation are tightly coupled through systemic and local regulation. A wave of bone formation follows each cycle of bone resorption to maintain skeletal homeostasis. Disturbing these processes leads to skeletal disorders, such as osteoporosis (1, 2) . Osteoporosis is the most common metabolic bone disease, affecting both men and women aged .50 years in Western countries (3) . It is characterized by a decrease in bone mass and defects in bone tissue that compromise bone strength and increase the risk of fractures (4).
The bone marrow niche is an interactive environment of autocrine, paracrine, and endocrine activities. Different cellular compartments and cell populations serve to regulate skeletal homeostasis. Bone marrow adipose tissue (MAT) is an important component of this niche. Bone marrow adipocytes have a moderate number of mitochondria, and express a mixture of white and brown fat markers (5) . MAT can be found in trabecular bone in the femur, tibia, and vertebrae and fills nearly the entire marrow cavity by the third decade of human life (6) .
Marrow fat may participate in lipid metabolism to provide localized energy by clearing and storing circulating triglycerides (7) . MAT responds to systemic changes in energy metabolism, expanding in volume with aging, estrogen deficiency, diabetes, thiazolidinedione antidiabetic therapy, caloric restriction, and anorexia nervosa (8) (9) (10) (11) (12) (13) . Increased MAT is accompanied by a concomitant decline in bone mass and strength (14) , but the mechanisms underlying the increase in marrow fat and bone destruction are not well understood.
Mammalian sirtuins are nicotinamide adenine nucleotide-dependent protein deacetylases (15) (16) (17) that play crucial roles in major metabolism pathways (18) . Among the three sirtuins that localize to the mitochondria, sirtuin-3 (Sirt3) is the best characterized (19) . Sirt3 has an important role in numerous facets of energy and nutrient metabolism, particularly in regulating fatty acid oxidation in response to calorie restriction or a high-fat diet. During caloric restriction, Sirt3 activates enzymes such as 3-hydroxy-3-methylglutaryl-CoA synthase 2, which generates ketones (20) , and long-chain acyl-CoA dehydrogenase, which oxidizes long-chain fatty acids (21) . By contrast, a high-fat diet can lead to a reduction in Sirt3 expression and activity in the liver and skeletal muscle and to a general hyperacetylation of mitochondrial proteins in rats (21) (22) (23) . In mice lacking Sirt3, a high-fat diet induces overexpression of stearoyl-CoA desaturase 1, a fatty acid synthesis enzyme (24) . Thus, Sirt3 regulates metabolism of fatty acids by controlling the activity of several liver proteins through regulation of their acetylation status. Sirt3 also plays an important role in mitochondrial respiration to regulate basal adenosine triphosphate levels. Sirt3 deacetylates and activates components of the electron transport chain to increase oxidative phosphorylation to increase adenosine triphosphate production (22, (25) (26) (27) . Sirt3 increases the ability of mitochondria to dissipate reactive oxygen species (ROS) generated as a byproduct of oxidative phosphorylation, thereby reducing oxidative damage in the liver (28) (29) (30) (31) .
Sirt3 is a critical factor in multiple metabolic and aging disorders including cardiovascular disease, age-related hearing loss, cancer, obesity, and type 2 diabetes (32). Bone marrow metabolism has been shown to be tightly linked with systemic metabolism (5, 33) . However, little is known about the role of Sirt3 in regulating bone marrow metabolism. In a recent report, Huh et al. (34) demonstrated that 8-week-old mice deficient in sirt3 were osteopenic, suggesting a positive role of Sirt3 during the development of peak bone mass. In the current study, we explored role of Sirt3 in regulating bone mass in aging mice. Unexpectedly, we found that Sirt3 overexpression increased adipogenesis and osteoclastogenesis in aged mice, and produced a corresponding decrease in bone mass. The osteoclastogenic effect appears to involve activation of the mechanistic target of rapamycin (mTOR) pathway by Sirt3.
Materials and Methods

Animals
Sirt3
flox/flox mice on the C57BL/6 background (35) were mated to actin-Cre mice, also on C57BL/6 background. This model has been to create lox-stop-lox Sirt3 transgenic (Sirt3Tg) mice that will allow Sirt3 expressed in a tissue-specific manner for all the tissues of interest. This Sirt3 transgene was constructed by combining the CMV enhancer/actin promoter, the b-geo gene flanked by two loxP sites, and a C-terminal FLAGtagged Sirt3. In the absence of Cre recombinase expression, the stop codon of the b-geo gene effectively stops translation before the Sirt3-FLAG open reading frame. In the presence of the Cre recombinase, the b-geo is excised from the construct, and Sirt3-FLAG is driven by the actin promoter. Crossing of this line with a transgenic mouse carrying an actin promoter-Cre led to the expression of Sirt3-FLAG in tissues. Animals were maintained on a standard chow diet, given free access to tap water, and housed in a room with a 12-hour light and 12-hour dark cycle and an ambient temperature of 22°C. All protocols were approved by the Animal Use Committee of the San Francisco Veterans Affairs Medical Center. Analyses were performed with male mice at 3 and 13 months were characterized, unless otherwise indicated. Age-and sex-matched control and wildtype mice were used as controls.
Adipocyte differentiation
The marrow was flushed from the long bones of 13-monthold Sirt3Tg and control mice and isolated bone marrow stromal cells (BMSCs) were cultured in primary culture medium (PCM). The cells were plated onto six-well plates at 10 3 10 6 cells per well for adipogenic differentiation. The PCM was replaced with secondary adipogenic differentiation medium (addition of 1 mM rosiglitazone, 1 mM dexamethasone, 5 mg/mL insulin, and 500 mM 3-isobutyl-1-methylxanthine) at day 8 of postculture. After 2 days, this medium was replaced with PCM containing 5 mg/mL insulin for 2 additional days, and then cells were maintained in PCM until day 16 (36) . At day 16, cells were fixed in 10% neutral buffered formalin (NBF; Fisher Scientific, Pittsburgh, PA). After fixation, cells were stained with Oil Red O (Sigma-Aldrich, St. Louis, MO) to assess adipogenesis. Cells were rinsed several times with distilled water to remove excess stain. Images were acquired at 310 with a Zeiss Axioplan Imager M1 microscope (Carl Zeiss MicroImaging, Thornwood, NY) fitted with a motorized stage, and blinded analyses were performed using image-analysis software (Bioquant Image Analysis Corp., Nashville, TN).
Microcomputed tomography
Femurs and tibiae from 3-and 13-month-old mice were isolated and cleaned of adherent tissue. Before microcomputed tomography (micro-CT) analysis, bones were fixed for 1 to 2 days in NBF, washed, and stored in 70% ethanol for micro-CT scanning. The femurs were imaged using a micro-CT 50 specimen scanner (SCANCO Medical AG, Bruttisellen, Switzerland). Imaging of cancellous bone was carried out at the distal metaphysic femur, and imaging of diaphyseal cortical bone was carried out at the tibiofibular junction. All images were obtained using an X-ray energy of 55 kV and potential of 109 mA, with a voxel size of 10 mm on each side and an integration time of 1000 ms. Quantitative analyses were carried out using the SCANCO Evaluation Program version 6.0 (SCANCO Medical). The cancellous region of interest was at a distance of 0.30 to 1.35 mm from the primary spongiosa. Cortical bone was assessed using a global thresholding protocol with segmentation values of 0.8/1/365.
Generation of osteoclasts
Bone marrow cells were obtained from the femur and tibia of male mice, and bone marrow macrophages were cultured in primary culture medium a-minimum essential medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (Sigma-Aldrich) in the presence of 10 ng/mL macrophage colony-stimulating factor (R&D Systems, Minneapolis, MN) for 2 days. Osteoclasts were generated by stimulating bone marrow macrophages with 20 ng/mL macrophage colony-stimulating factor and 25 ng/mL receptor activator of nuclear factor k-B ligand (RANKL; R&D System) for an additional 6 to 8 days. Cells were then fixed in NBF and stained for tartrate resistant acid phosphatase (TRAP; Sigma-Aldrich) to assess osteoclastogenesis. Cells were rinsed several times with distilled water to remove excess stain. Images were acquired at 310 with a Zeiss Axioplan Imager M1 microscope (Carl Zeiss MicroImaging) fitted with a motorized stage, and blinded analyses were performed using image-analysis software (Bioquant Image Analysis Corp.).
Generation of osteoclast precursors from spleen
Spleens were removed from mice and gently smashed between a strainer and the bore of a syringe in 10 mL primary culture medium on a petri dish. Cells were then transferred to a 15-mL tube and centrifuged. The supernatant was discarded and the pellet was washed, resuspended, and recentrifuged. The cells were resuspended, counted, and plated 3 days in primary culture medium. Cells were then lysed for western blotting or for isolation of RNA for quantitative polymerase chain reaction (PCR) of relevant genes.
Immunoblotting
Cells were harvested, and cell lysates were subjected to immunoblot analysis with specific antibodies against P-mTOR 
Static histomorphometry
After micro-CT analysis, the undecalcified bone samples were embedded in methyl methacrylate and sectioned with Jung 2065 and 2165 microtomes (Leica, Bannockburn, IL). Sectioned bones were processed for TRAP staining and von Kossa tetrachrome staining as previously described (37, 38) . Additional bones were decalcified and embedded in paraffin and hematoxylin and eosin staining was carried out. Mosaic-tiled images were acquired at 320 with a Zeiss Axioplan Imager M1 microscope (Carl Zeiss MicroImaging) fitted with a motorized stage. The tiled images were stitched and converted to a single image using the Axiovision software (Carl Zeiss MicroImaging) and blinded analyses were performed using image-analysis software (Bioquant Image Analysis Corp.). Adipocytes were assessed in the 1.5-mm 2 region of interest below the epiphyseal growth plate of the proximal tibia. TRAP positive osteoclasts were quantified per square millimeter in the 4.5-mm 2 region of interest at the midpoint of the epiphyseal growth plate containing the provisional calcification layer and the primary spongiosa enclosing the area of greatest intensity of TRAP localization.
Osteoblast differentiation
The marrow was flushed from the long bones as previously described procedure (38, 39) with PCM consisting of a-modification of Eagle's medium, supplemented with 10% fetal bovine serum (Hyclone Laboratories, Logan, UT; catalog no. SH30396.03, lot no. AVC66310), 100 U/mL penicillin, 100 g/mL streptomycin, and 0.25 mg/mL fungizone (Life Technologies, Carlsbad, CA) from 52-week-old male mice. The cells were collected in PCM and plated onto six-well plates at a density 1 3 10 6 cells per well for osteoblastic differentiation. After BMSCs had been maintained in primary medium for 5 days, the medium was aspirated and replaced with secondary osteogenic differentiation medium (PCM containing 50 mg/mL ascorbic acid and 3 mM b-glycerophosphate) to initiate osteoblast differentiation. At day 28, cells were fixed in NBF. Alkaline phosphatase staining was performed as previously described to assess osteoblastogenesis at the end of the 28-day differentiation protocol (37) . Briefly, the presence of alkaline phosphatase activity was assessed using a leukocyte alkaline phosphatase kit (Sigma-Aldrich). Staining solution was aspirated and stained dishes were rinsed twice with distilled water for assessing mineralized nodules. For quantification of the colony formation and mineralized nodules, stained cultures were scanned and analyzed using an image analysis system (Bioquant Image Analysis Corp.).
Serum chemistry
Before killing mice, blood was collected from abdominal inferior vein at the time of euthanasia and then processed in MicroTainer serum separator tubes (BD Biosciences, San Jose, CA). Serum procollagen type 1 amino-terminal propeptide (PINP) and serum pyridinoline (PYD) measurements were carried out using the rat/mouse PINP EIA Kit AC-33F1 from Immunodiagnostic Systems (Scottsdale, AZ) and the Metra Biosystems Serum PYD Kit 8019 (Metra Biosystems Inc., Santa Clara, CA) according to manufacturers' directions.
RNA extraction and real-time PCR
Tissue samples were isolated and kept frozen in liquid nitrogen until processing. Before freezing, epiphyses were removed, and bone marrow was flushed from tibial bone samples. Frozen tissues were pulverized using a biopulverizer (Biospec Products, Inc., Bartlesville, OK), followed by RNA extraction using RNA STAT60 (Tel-Test, Inc., Friendswood, TX) and subsequent purification using the Micro-to-Midi Total RNA Purification Kit (Invitrogen). Total RNA from BMSCs and osteoblasts were extracted using PureLink RNA Mini Kit (Life Technologies). Complementary DNA was synthesized using TaqMan Reverse Transcription reagents (Applied Biosystems, Inc., Foster City, CA) and random hexamer primers according to the recommendations of the manufacturer. Gene amplification using primers (Table 1) was measured with SYBR Green using the ABI Prism 7300 real-time thermocycler (Applied Biosystems, Inc.). Analysis was carried out using the SDS software supplied with the thermocycler. All reactions were run in triplicate. After data collection, the messenger RNA (mRNA) copy number of a specific gene in total RNA was calculated with a standard curve generated with serially diluted plasmids containing PCR amplicon sequences and normalized to total RNA with L19 as an internal control for assessment of osteoblastic and mitochondrial biogenesis markers.
Statistics
Statistical analyses were performed using a two-tailed unpaired Student t test or analysis of variance analysis, and each series of experiments was repeated at least three times. Results are presented as mean 6 standard error of the mean.
Results
Sirt3 promotes adipogenesis in bone marrow cells and adipogenesis in vitro
Growing evidence suggests that aging is associated with a decline in mitochondrial function and dynamics (40) . With age, bone marrow is progressively populated by adipocytes (41, 42) , and this is associated with a decline in bone mass and strength (43) (44) (45) . Sirt3 is a critical factor in multiple metabolic and aging disorders including cardiovascular disease, age-related hearing loss, cancer, obesity, and type 2 diabetes (32). Metabolic activity within the bone marrow has been shown to be tightly linked with systemic metabolism (5, 33) . However, little is known about the role of Sirt3 in regulating bone marrow metabolic activity.
To determine whether Sirt3 produce changes in the bone marrow environment, we generated mice overexpressing Sirt3. Crossing transgenic mice carrying a Sirt3 flox/flox gene to transgenic mice carrying b-Actin promoter-Cre construct led to the expression of the fusion protein SIRT3-FLAG in the bone marrow and other tissues, with an increase in SIRT3 level of ;3.5-fold (35) . Mice overexpressing Sirt3 in Actin-Cre expressing cells, hereafter called Sirt3Tg, were born at normal Mendelian frequencies and are viable. Sirt3Tg mice appeared to be normal at birth and were not different from wild-type mice with respect to size and body weight (data not shown).
To examine the effect of Sirt3 on bone marrow adipogenesis, we counted adipocytes in longitudinal tibial sections of 13-month-old male Sirt3Tg and control mice (n = 5 to 9) stained with hematoxylin and eosin staining. Sirt3Tg mice exhibited more adipocytes in the tibia when compared with control mice [92 6 6.0 vs 11 6 0.1 in Sirt3Tg and control mice, respectively, P , 0.05; Fig. 1(a-d) ]. To assess the basis of this increase, we cultured BMSCs and examined their ability to differentiate into adipocytes. BMSCs isolated from Sirt3Tg mice generated a significantly larger number of adipocytes than BMSCs from control mice [adipocyte number per square millimeter was 1.74 6 0.185 in Sirt3Tg cultures compared with 0.59 6 0.061 in control cultures, P = 0.04; Fig.  1(e-h) ]. Thus, overexpression of Sirt3 in BMSCs promotes adipocyte differentiation in vivo and in vitro.
Sirt3Tg male mice exhibit low trabecular bone mass
With aging, bone marrow is progressively populated by adipocytes (41, 42) , and this is associated with a decline in bone mass and strength (43) (44) (45) . Our next step was therefore to assess bone mass including trabecular and cortical bone mass in Sirt3Tg vs control mice. To assess cancellous bone mass in Sirt3Tg mice, femurs from 13-month-old mice were examined using both micro-CT and histomorphometry. Sirt3Tg mice exhibited a reduction Abbreviations: Alk, alkaline phosphatase; ERRa, estrogen-related receptor a; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; L19, mitochondrial ribosomal protein L19; OC, osteocalcin; OPG, osteoprotegerin; Runx2, runt-related transcription factor 2.
in bone mass compared with their control littermates [ Fig. 2(a-h) ]. This reduction was most pronounced in trabecular bone of male mice, as confirmed by histomorphometric analysis [ Fig. 2 (g) and 2(h)]. These differences can be clearly observed by comparing representative three-dimensional reconstruction images of distal femurs. The decrease in bone volume fraction was associated with a substantially reduced trabecular number with no significant change in trabecular thickness or connectivity [ Fig. 2(a-f) ]. In contrast to our results in males, we found no difference in cancellous bone mass in the age-matched, Sirt3Tg female mice compared with controls (Supplemental Fig. 1 ). Trabecular bone mass from young (3-month-old) Sirt3Tg and littermate control mice were assessed by micro-CT, and there was no significant difference [ Fig. 3(a-h) ].
Overexpressing Sirt3 causes cortical bone loss in male mice
To assess the role of Sirt3 overexpression in cortical bone, we examined the tibiofibular juncture in 13-monthold male Sirt3Tg and control mice (n = 5 to 9) using micro-CT. A significant reduction in cortical thickness was observed in Sirt3Tg compared with control male mice (0.201 6 0.003 vs 0.220 6 0.004 mm in Sirt3Tg and control mice, respectively, P = 0.012). In line with the reduction in cortical thickness, the bone volume fraction of cortical bone was decreased in Sirt3Tg compared with control [ Fig. 4(a-e) ]. However, there was no difference in cortical bone parameters of young (3-month-old) Sirt3Tg vs littermate control mice [ Fig. 5(a-e) ].
It has been recently demonstrated that the young mice deficient in Sirt3 were osteopenic, suggesting a positive role of sirt3 during the development of peak bone mass (34) . In a parallel experiment, we assessed both cancellous and cortical bone in 6-month-old Sirt3 deficient mice using micro-CT and found no obvious bone phenotype (Supplemental Fig. 2) . Surprisingly, deletion of the Sirt3 gene did not significantly affect body composition, either (Supplemental Fig. 2) . The results suggest that the physiological role of Sirt3 in bone is age dependent. Young mice require Sirt3 for normal skeletal homeostasis, but the skeletal defect in young Sirt3 deficient mice normalizes with age.
Sirt3 overexpression decreases osteoblastic markers in vivo
The mechanisms underlying the loss of bone and accumulation of marrow fat associated with aging remain undefined. Increased adiposity with aging has been studied mainly from the perspective of an imbalance between adipogenesis and osteoblastogenesis (46) . Adipocytes and osteoblasts are both derived from mesenchymal stem cells, and skeletal aging is characterized by decreased osteoblastogenesis and increased adipogenesis (42) .
To determine if the low bone mass observed in Sirt3Tg male mice was associated with a deficit in bone-forming osteoblasts, we analyzed osteoblastic differentiation of multipotent bone marrow cells. BMSCs isolated from the long bones of control and Sirt3Tg mice exhibited no difference in their ability to differentiate into osteoblastic cells, assessed by alkaline phosphatase staining (Supplemental Fig. 3A and 3B ). To confirm this result, we evaluated the expression of gene markers associated with osteoblastogenesis including runt-related transcription factor 2, alkaline phosphatase, osteocalcin, collagen type 1 (col1), and osteoprotegerin. We found no significant differences in the expression of these genes in differentiated osteoblasts of Sirt3Tg vs control mice (Supplement Fig. 3C ). However, overexpressing Sirt3 decreased bone marrow progenitor proliferation and mRNA expression of osterix and increased RANKL mRNA expression in BMSCs derived osteoblast cultures at day 25 postculture (Supplemental Fig. 4 ). In addition, the expression of peroxisome proliferator-activated receptor-g (PPAR-g ), C/EBP, SOD2, and catalase in these cultures was upregulated in osteoblasts derived from Sirt3Tg mice (Supplemental Fig. 4B ). Interestingly, unlike the slight changes in the expression of osteoblast marker genes in in vitro cultured osteoblasts, there is a significant decrease in osteocalcin and col1 expression in RNA isolated from long bones of Sirt3Tg compared with control ( Supplemental Fig. 3D ). It was also found that the mineral appositional rate and the level of the serum bone formation marker PINP were significantly lower in 8-month-old male Sirt3 Tg mice than in age-matched controls (Supplemental Fig. 5 ). These results suggest that osteoblastogenesis was suppressed in the aged Sirt3Tg mice. 
Positive role of Sirt3 in osteoclastogenesis and bone resorption
Histomorphometric assessment by TRAP staining revealed a significant increase (2.5-fold) in the number of TRAP positive cells/bone surface in Sirt3Tg mice compared with controls [P , 0.03; Fig. 6 (b) and 6(c)]. Accordingly, there was an almost twofold increase in osteoclastogenesis in vitro (P , 0.01) by Sirt3Tg bone marrow cells grown in the presence of CSF-1 and RANKL in comparison with control [ Fig. 6(d) and 6(e) ]. In agreement with the increase in osteoclastogenesis in Sirt3Tg mice, levels of serum PYD cross-links, a marker of bone resorption, tended to be increased in these mice, although this did not achieve statistical significance [ Fig. 6(a) ]. We also assessed and found an increase in the gene expression of TRAP and cathepsin K, the enzymes determining bone resorption activity, in the osteoclast cultures derived from the 8-month-old Sirt3 Tg mice (Supplemental Fig. 6 ). These data support the notion that Sirt3 negatively regulates bone mass, at least in part, by increasing osteoclastic bone resorption.
Sirt3 regulates mTOR pathway in osteoclast precursors and mitochondrial biogenesis in bone marrow
Sirt3 activates mTOR in osteoclast precursors mTOR is an atypical protein kinase that couples energy, nutrient abundance, and oxygen levels to regulate growth and metabolism (47, 48) . The mTOR pathway is involved in osteoclastogenesis, and osteoclasts constitutively express not only mTOR but also raptor and rictor (47, 48) . Sirt3 has an important role in regulating cellular energy and nutrient metabolism (32) . The spleen has been shown to be a reservoir of osteoclast precursors (OCPs) and can provide a cleaner population of monocytes lineage cells (49) . We therefore assessed the involvement of mTOR in osteoclastogenesis using OCPs derived from the spleens of SirtTg vs control mice. As shown in Fig. 7(a) , phosphorylation at serine 2448 on mTOR was increased in OCPs from Sirt3Tg compared with the control. In consequence, raptor and rictor-which are associated with mTOR to form mTOR complex 1 and mTOR complex 2, respectively-were increased. These results suggest that Sirt3 is involved in regulating mTOR, more specifically raptor (mTOR complex 1) and rictor (mTOR complex 2) in osteoclast development.
PPAR-g coactivator 1-b-dependent induction of Sirt3 in bone marrow niche
Osteoclasts are acid-secreting multinuclear cells that have high energy demands and contain abundant mitochondria (50) . PPAR-g coactivator (PGC)-1-b, has been shown to regulate osteoclastogenesis (50) . Sirt3 is a critical regulator of energy metabolism in mitochondria as mentioned previously. Because osteoclastogenesis is increased positively with Sirt3 expression, we examined the involvement of PGC-1-b as well as mitochondrial biogenesis markers in the bone marrow environment of Sirt3Tg compared with control mice. In this experiment, we used RNA from whole tibias without separation of bone and marrow to include all cell lineages in bone tissue. As expected, the expression of PGC-1-b, cyclophillin A, cytochrome C, and estrogen-related receptor a (ERRa) were enhanced in Sirt3 bone tissue [ Fig. 7(b-e) ]. In addition, osteoclasts were cultured using the nonadherent bone marrow cells derived for the 8-month-old male Sirt3 Tg mice. The same panel of genes was examined at the mRNA level and no obvious differences were observed (Supplemental Fig. 6 ). Taken together, these results suggest that Sirt3 increases osteoclastogenesis by upregulating PGC-1-b and mitochondrial biogenesis genes. We also assessed PPAR-g, apelin, and tumor necrosis factor (TNF)-a gene expressions in bone marrow of Sirt3Tg vs littermates. The expression of PPAR-g, the adipokine apelin, and TNF-a was increased in Sirt3Tg bone [ Fig. 7(f-h) ].
Discussion
A previous study demonstrated that knockout of the sirt3 gene led to an osteopenic phenotype in young mice (34) .
However, the physiological role of Sirt3 on bone homeostasis during aging is not clear. In the current study, we have examined the effects of Sirt3 overexpression and Sirt3 deletion in older (6-month-old) mice. We found that Sirt3 knockout did not lead to any obvious bone phenotype (Supplemental Fig. 2) , whereas Sirt3 overexpression was associated with significant bone loss in older mice, but not in young mice. These results indicate that the role of Sirt3 and the response to Sirt3 overexpression are both age dependent.
In this study, we demonstrated that Sirt3 is a positive regulator of adipogenesis and osteoclastogenesis in aging male mice and that this regulation results in a reduced bone mass. Aged male Sirt3Tg mice exhibited trabecular and cortical bone loss, and these effects were associated with increased marrow adipogenesis, increased osteoclast numbers, and decreased expression of osteoblastic Sirt3 has been shown to play an important role in the regulation of fatty acid b-oxidation (21) and energy metabolism (26) in several tissues such as liver, heart, skeletal muscle, and brown adipose tissues (31, 32) . The role of mitochondrial Sirt3 in bone marrow tissue and bone marrow fat metabolism remains unexplored. In the current study, we found that Sirt3 stimulates adipocyte formation in the bone marrow niche as well as adipogenesis from bone marrow mesenchymal stem cells. Bone marrow fat responds to physiologic and pathologic alterations in energy metabolism status by changing volume and metabolic activity (51) . Studies in different populations using different measurement techniques have established that increased bone MAT is associated with lower bone density and prevalent vertebral fracture, but the mechanisms underlying this association are not clear (52) . Concordant with these observations, we found that Sirt3 stimulates marrow adipogenesis in association with bone loss, suggesting that Sirt3 is an important mediator of this well-known relationship.
We also found that the effect of Sirt3 overexpression on cortical bone mass is more pronounced in males than females. The basis for this sex difference is unclear, but might relate to the previous observations that sirtuins can regulate steroid hormone receptor signaling. Sirt1, the most extensive studied sirtuin, has shown to be involved in regulating of steroid hormone signaling through a variety of molecular mechanisms, and a role for the sirtuins in the regulation of steroid hormone receptor signaling is emerging (53) . Our findings of a sexual dimorphic phenotype are consistent with other sirtuin related transgenic mouse models (54) (55) (56) . Sirt1 haploinsufficient (Sirt1 +/2 ) female mice exhibit a significant reduction in bone mass characterized by decreased bone formation resulting from altered acetylation of the Sost promoter and increased marrow adipogenesis (54) . Female (but not male) mice lacking Sirt1 in proopiomelanocortin neurons display enhanced sensitivity to diet-induced obesity (55) . Moreover, nicotinamide phosphoribosyltransferaseheterozygous female (but not male) mice showed impaired glucose tolerance and reduced insulin secretion (56) . Sirt3 activates oxidative stress response genes through its deacetylase activity to limit the production of ROS, reducing oxidative stress and promoting efficient energy production with aging (31, 32). Mitochondrial energy, ROS production, and mitochondrial biogenesis play crucial roles in the regulation of osteoclast differentiation and function (57, 58) . The role of Sirt3 in the regulation of osteoclastogenesis through its function in mitochondria has not been fully elucidated. Our study identified a new role for Sirt3 in aging male mice as a positive regulator of osteoclast differentiation via activation of the mTOR pathway and mitochondrial biogenesis. We found that Sirt3 overexpression significantly enhanced osteoclast differentiation, suggesting that Sirt3 regulates bone homeostasis through modulating osteoclast differentiation. Consistent with this, Sirt3Tg mice exhibited reduced bone mass due primarily to more osteoclasts. We further demonstrated a positive role of Sirt3 in osteoclastogenesis associated with activation of the mTOR pathway in osteoclast precursors and by coordinating of PGC-1-b and mitochondrial biogenesis markers ERRa, cytochrome C, and cyclophilin A and adipogenic markers apelin and TNF-a at the transcriptional level in bone marrow niche.
Our data suggest that Sirt3 has a positive role in osteoclastogenesis through the mTOR pathway. These findings stand in contrast to those from Huh et al. (34) , who recently reported that 8-week-old mice lacking Sirt3 displayed decreased trabecular bone mass and increased osteoclastogenesis. However, our results are consistent with their finding that Sirt3 was induced by PGC-1-b together with ERRa during RANKL-induced osteoclast differentiation. They suggested that Sirt3 may function as a negative feedback regulator of osteoclastogenesis through stabilization of AMPK protein. We suggest that in aging males, Sirt3 induces mitochondrial biogenesis and activates mTOR pathway to increase osteoclastogenesis. It is possible that the positive role of Sirt3 in promoting osteoclastogenesis (as seen in our study) is age dependent. Thus, we found that Sirt3 had little effect on skeletal homeostasis in young (3-month-old) mice. A limitation of our study is that we did not define in detail the age dependence of the role of Sirt3, and it thus remains uncertain when Sirt3 switches from a negative to a positive regulator of osteoclastogenesis. This will be an important issue to address in future studies.
In summary, our study uncovers a role for Sirt3 as a negative regulator of bone mass in aged male mice and suggests a connection between adipogenesis and osteoclastogenesis mediated by Sirt3. We found that Sirt3 activates the mTOR pathway and mitochondrial biogenesis in association with increased osteoclastogenesis. Aged Sirt3Tg male mice have decreased bone mass, particularly decreased cortical thickness associated with increased bone marrow fat and osteoclastogenesis with reduced osteoblastic markers osteocalcin and col1 in vivo. Our findings suggest that specific Sirt3 inhibitors may inhibit bone resorption and suppress bone marrow adiposity, thereby providing a novel strategy for the treatment of age-related osteoporosis.
